South San Francisco, United States
insitro, founded in 2018 and headquartered in the United States, is making strides in the Biotechnology industry with its novel approach to blending physical AI and causal biology. Under the leadership of AI pioneer Daphne Koller, the company is constructing the Virtual Human™, a sophisticated AI engine that deciphers human biology to unveil disease mechanisms and treatment pathways.
With its innovative TherML™ AI platform, insitro aims to propel the development of therapeutics, particularly in neuroscience and metabolic disorders. This cutting-edge strategy has attracted substantial investor interest, evidenced by a robust $400.00M in Series C funding on 01 March 2021.
Notable investors include CPP Investments, Two Sigma Ventures, Arch Venture Partners, and Andreessen Horowitz/a16z, among others. This backing underscores a shared belief in insitro's potential to redefine medicine through scalable biological insights and enhanced drug discovery.
